ArticleFrontiers in oncology2026
Early risk stratification and temporal biomarker patterns of trousseau syndrome-related cerebral infarction in lung cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Trousseau syndrome-related cerebral infarction (TSCI) is a severe complication of lung cancer, but tools for early risk stratification remain limited. Methods: In this retrospective case-control study, we enrolled 94 patients with newly diagnosed lung cancer and TSCI and 94 matched lung cancer controls without stroke at the First Affiliated Hospital of Zhengzhou University between 2021 and 2025. Using cases in which TSCI occurred at diagnosis or within 6 months thereafter, we developed and internally validated a five-variable model based on serum magnesium, international normalized ratio, prothrombin time, albumin-to-globulin ratio, and a history of hypertension. Concurrent-onset (Fulminant) and delayed-onset TSCI subgroups were compared across coagulation, inflammatory, tumor-burden, and nutritional domains. Temporal biomarker patterns were examined using locally estimated scatterplot smoothing (LOESS). Results: The model showed good discrimination (AUC = 0.861) and sample-specific calibration within the selected case-control sample. Fulminant TSCI showed pronounced abnormalities across coagulation/fibrinolysis, inflammatory, tumor-burden, and nutritional domains. Temporal analyses suggested heterogeneity in biomarker patterns: early-onset TSCI was associated with higher Ki67, neuron-specific enolase, and lactate dehydrogenase, whereas late-onset TSCI was more closely associated with higher triglyceride levels. Conclusions: These findings identify a set of routinely available clinical variables associated with early high-risk TSCI in patients with lung cancer. The proposed nomogram demonstrated favorable discriminative performance and may provide a useful framework for early risk stratification and clinical surveillance. Further validation in independent prospective cohorts would help to confirm its generalizability and support future clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.